Literature DB >> 30846037

Cholangiocarcinoma.

Adeel S Khan1, Leigh Anne Dageforde2.   

Abstract

Cholangiocarcinoma is a rare malignancy and accounts for 2% of all malignancies. Incidence is on the increase in the Western world. Cholangiocarcinoma arises from the malignant growth of the epithelial lining of the bile ducts and can be found all along the biliary tree. It can be classified into subtypes based on location: intrahepatic (arising from the intrahepatic biliary tract in the hepatic parenchyma), perihilar (at the hilum of the liver involving the biliary confluence) and distal (extrahepatic, often in the head of the pancreas). Margin status and locoregional lymph node metastases are the most important determinants of postsurgical outcomes.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cholangiocarcinoma (CCA); Extrahepatic cholangiocarcinoma (EHCCA); Intrahepatic cholangiocarcinoma (IHCCA); Klatskin tumor; Perihilar cholangiocarcinoma (PHCCA)

Mesh:

Year:  2019        PMID: 30846037     DOI: 10.1016/j.suc.2018.12.004

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  44 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Preliminary results in unresectable cholangiocarcinoma treated by CT percutaneous irreversible electroporation: feasibility, safety and efficacy.

Authors:  Maria Paola Belfiore; Alfonso Reginelli; Nicola Maggialetti; Mattia Carbone; Sabrina Giovine; Antonella Laporta; Fabrizio Urraro; Valerio Nardone; Roberta Grassi; Salvatore Cappabianca; Luca Brunese
Journal:  Med Oncol       Date:  2020-04-09       Impact factor: 3.064

Review 3.  Cholangiocarcinoma: novel therapeutic targets.

Authors:  Keisaku Sato; Shannon Glaser; Domenico Alvaro; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Expert Opin Ther Targets       Date:  2020-02-26       Impact factor: 6.902

Review 4.  Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.

Authors:  Massimiliano Cadamuro; Alberto Lasagni; Angela Lamarca; Laura Fouassier; Maria Guido; Samantha Sarcognato; Enrico Gringeri; Umberto Cillo; Mario Strazzabosco; Jose Jg Marin; Jesus M Banales; Luca Fabris
Journal:  Expert Opin Investig Drugs       Date:  2021-02-23       Impact factor: 6.206

5.  Missed Diagnosis of Cholangiocarcinoma Presenting with Atypical Symptoms.

Authors:  Ren Kawamura; Yukinori Harada; Taro Shimizu
Journal:  Eur J Case Rep Intern Med       Date:  2021-01-26

6.  Underexpression of miR-126-3p in Patients with Cholangiocarcinoma.

Authors:  Lucas Poleto Spinola; Gabriel F Vieira; Rafael Fernandes Ferreira; Maria C J Calastri; Graciele D Tenani; Franciana L Aguiar; Ilka F Santana Ferreira Boin; Larissa B E Da Costa; Maria Fernanda Chaim Correia; Eliane M Zanovelo; Daniele C B De Souza; Rita C Martins Alves Da Silva; Renato Ferreira Da Silva; Ana Margarida Coelho Abrantes; Maria Filomena R R Botelho; Jose Guilherme L R Tralhão; Doroteia R S Souza
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

7.  OPCML Exerts Antitumor Effects in Cholangiocarcinoma via AXL/STAT3 Inactivation and Rho GTPase Down-regulation.

Authors:  Ricuphan Khamko; Jureerut Daduang; Chatri Settasatian; Temduang Limpaiboon
Journal:  Cancer Genomics Proteomics       Date:  2021 Nov-Dec       Impact factor: 4.069

8.  IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.

Authors:  Stephen P Hack; Wendy Verret; Sohail Mulla; Bo Liu; Yulei Wang; Teresa Macarulla; Zhenggang Ren; Anthony B El-Khoueiry; Andrew X Zhu
Journal:  Ther Adv Med Oncol       Date:  2021-07-31       Impact factor: 8.168

9.  Short- and long-term outcomes after hemihepatectomy for perihilar cholangiocarcinoma: does left or right side matter?

Authors:  Lotte C Franken; Pim B Olthof; Joris I Erdmann; Otto M van Delden; Joanne Verheij; Marc G Besselink; Olivier R Busch; Thomas M van Gulik
Journal:  Hepatobiliary Surg Nutr       Date:  2021-04       Impact factor: 8.265

Review 10.  Melatonin and circadian rhythms in liver diseases: Functional roles and potential therapies.

Authors:  Keisaku Sato; Fanyin Meng; Heather Francis; Nan Wu; Lixian Chen; Lindsey Kennedy; Tianhao Zhou; Antonio Franchitto; Paolo Onori; Eugenio Gaudio; Shannon Glaser; Gianfranco Alpini
Journal:  J Pineal Res       Date:  2020-03-04       Impact factor: 13.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.